CD5

Across TCGA pan-cancer cohorts, CD5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD5 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where CD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	15	view →
LUAD	DFS	Tertile	All	0.796	0.512	.010	9	view →
HNSC	DFS	Tertile	All	0.915	1.000	.018	6	view →
UCEC	OS	Quartile	All	1.000	0.781	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD5–PDAC (DFS)

Open the PDAC breakdown →